Lucid Diagnostics is a commercial-stage medical diagnostics technology company focused on patients with gastroesophageal reflux (GERD) disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). Co.'s lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a noninvasive office procedure, serving as a screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients. We show 5 historical shares outstanding datapoints in our LUCD shares outstanding history coverage, used to compute LUCD market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing LUCD market cap history over the course of time is important for investors
interested in comparing LUCD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of LUCD versus a peer is one thing; comparing
LUCD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like LUCD can fluctuate over the course of history.
With this page we aim to empower investors researching LUCD by allowing them to research the LUCD market cap history. |
Free LUCD Email Alerts:
Video: The Importance of Market Cap
